Sotera Health Company (SHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jaden Rismay
JPMorgan Chase & Co, Research Division

Thanks, everyone, for joining us today. Welcome to the JPMorgan Healthcare Conference. My name is Jaden Rismay, and I’m on the Life Science Tools team here. I’m pleased to be joined by Sotera Health, CEO, Michael Petras. So I’ll turn it over here in a second to Michael to get started with the presentation. Afterwards, we’ll do the standard Q&A session. And so with that, please take it away, Michael.

Michael Petras
Chairman & CEO

Great. Thanks, Jaden, and good morning, everybody, and I appreciate the JPMorgan team for hosting us today. Obviously, we’ve got forward-looking statements, and you can refer to our securities filings on our website or our SEC filings for any reconciliation of non-GAAP matters. Today, I want to cover 3 topics. One, the crucial role that Sotera Health plays in health care, try to just give an overview of the company for folks that may not be as familiar with the company. Secondly, then I’ll cover our strong and consistent financial performance over many years of consistent performance. And then last one, our path to driving value long term for shareholders. So that will be the focus of today’s discussion.

Safeguarding global health, that is the mission of the company, Sotera Health. Sotera, for the folks that aren’t familiar with Sotera, the word comes from Sotera, the Greek goddess of safety, and really, when we look at what our mission is in this company, it’s safeguarding global health across our 3 businesses, Sterigenics, Nordion and Nelson Labs. We have over 5,000 customers in 50 countries, over 3,100 employees globally. We provide end-to-end solutions across